< 1 minute read
Sep. 18, 2021

Remogliflozin Etabonate: SGLT1-Sparing Oral SGLT2 Inhibitor Prodrug

remogliflozin etabonate

SGLT1-sparing oral SGLT2 inhibitor prodrug launched in India for diabetes, 100 mg BID from mouse urine drug metabolite and opt. Bioorg. Med. Chem., Jan. 22, 2021 Kissei Pharma / Toho University, JP

drughunter.com
Drug Hunter Team

The Kissei SGLT2 inhibitor prodrug, remogliflozin etabonate , is an SGLT1-sparing oral drug launched in 2019 in India for the treatment of type 2 diabetes.  Interestingly, the lead for this drug was a metabolite identified from mouse urine after treatment with a Wyeth-Ayerst antihyperglycemic agent of previously unknown mechanism.

Loading...

twitterlinkedinemail

Other molecules you may be interested in